XRAY Relative Valuation
XRAY's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, XRAY is overvalued; if below, it's undervalued.
Historical Valuation
DENTSPLY SIRONA Inc (XRAY) is now in the Undervalued zone, suggesting that its current forward PE ratio of 7.26 is considered Undervalued compared with the five-year average of 16.11. The fair price of DENTSPLY SIRONA Inc (XRAY) is between 27.23 to 40.19 according to relative valuation methord. Compared to the current price of 11.27 USD , DENTSPLY SIRONA Inc is Undervalued By 58.61%.
Relative Value
Fair Zone
27.23-40.19
Current Price：11.27
58.61%
Undervalued
7.26
PE
1Y
3Y
5Y
Trailing
Forward
7.03
EV/EBITDA
DENTSPLY SIRONA Inc. (XRAY) has a current EV/EBITDA of 7.03. The 5-year average EV/EBITDA is 11.97. The thresholds are as follows: Strongly Undervalued below 6.01, Undervalued between 6.01 and 8.99, Fairly Valued between 14.95 and 8.99, Overvalued between 14.95 and 17.94, and Strongly Overvalued above 17.94. The current Forward EV/EBITDA of 7.03 falls within the Undervalued range.
9.11
EV/EBIT
DENTSPLY SIRONA Inc. (XRAY) has a current EV/EBIT of 9.11. The 5-year average EV/EBIT is 14.50. The thresholds are as follows: Strongly Undervalued below 7.91, Undervalued between 7.91 and 11.21, Fairly Valued between 17.80 and 11.21, Overvalued between 17.80 and 21.09, and Strongly Overvalued above 21.09. The current Forward EV/EBIT of 9.11 falls within the Undervalued range.
0.62
PS
DENTSPLY SIRONA Inc. (XRAY) has a current PS of 0.62. The 5-year average PS is 1.92. The thresholds are as follows: Strongly Undervalued below 0.32, Undervalued between 0.32 and 1.12, Fairly Valued between 2.72 and 1.12, Overvalued between 2.72 and 3.52, and Strongly Overvalued above 3.52. The current Forward PS of 0.62 falls within the Undervalued range.
4.22
P/OCF
DENTSPLY SIRONA Inc. (XRAY) has a current P/OCF of 4.22. The 5-year average P/OCF is 14.09. The thresholds are as follows: Strongly Undervalued below 4.39, Undervalued between 4.39 and 9.24, Fairly Valued between 18.94 and 9.24, Overvalued between 18.94 and 23.79, and Strongly Overvalued above 23.79. The current Forward P/OCF of 4.22 falls within the Strongly Undervalued range.
13.46
P/FCF
DENTSPLY SIRONA Inc. (XRAY) has a current P/FCF of 13.46. The 5-year average P/FCF is 19.54. The thresholds are as follows: Strongly Undervalued below 5.29, Undervalued between 5.29 and 12.42, Fairly Valued between 26.67 and 12.42, Overvalued between 26.67 and 33.80, and Strongly Overvalued above 33.80. The current Forward P/FCF of 13.46 falls within the Historic Trend Line -Fairly Valued range.
DENTSPLY SIRONA Inc (XRAY) has a current Price-to-Book (P/B) ratio of 1.52. Compared to its 3-year average P/B ratio of 1.84 , the current P/B ratio is approximately -17.15% higher. Relative to its 5-year average P/B ratio of 2.01, the current P/B ratio is about -24.15% higher. DENTSPLY SIRONA Inc (XRAY) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 5.41%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 5.36% , the current FCF yield is about -100.00% lower.
1.52
P/B
Median3y
1.84
Median5y
2.01
3.54
FCF Yield
Median3y
5.41
Median5y
5.36
Competitors Valuation Multiple
The average P/S ratio for XRAY's competitors is , providing a benchmark for relative valuation. DENTSPLY SIRONA Inc Corp (XRAY) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -4.94%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of XRAY decreased by 39.50% over the past 1 year. The primary factor behind the change was an decrease in Revenue Growth from 951.00M to 904.00M.
The secondary factor is the Margin Expansion, contributed -9.03%to the performance.
Overall, the performance of XRAY in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is DENTSPLY SIRONA Inc (XRAY) currently overvalued or undervalued?
What is DENTSPLY SIRONA Inc (XRAY) fair value?
How does XRAY's valuation metrics compare to the industry average?
What is the current P/B ratio for DENTSPLY SIRONA Inc (XRAY) as of Dec 05 2025?
What is the current FCF Yield for DENTSPLY SIRONA Inc (XRAY) as of Dec 05 2025?
What is the current Forward P/E ratio for DENTSPLY SIRONA Inc (XRAY) as of Dec 05 2025?